Petros Pharmaceuticals, Inc. Amortization of Debt Issuance Costs
Petros Pharmaceuticals, Inc. (PTPI) reported Amortization of Debt Issuance Costs of $12.50 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-03-31
- Petros Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-03-31 was $12.50K.
- Petros Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2021 was $12.50K, a 66.67% decline from fiscal 2020.
- Petros Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2020 was $37.50K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 derived: sum of 3 quarters · filed 2022-03-31 | $12.50K 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $12.50K 10-Q · filed 2021-11-15 | $25.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $12.50K 10-Q · filed 2021-08-16 | $25.00K derived: sum of 3 quarters · filed 2022-03-31 | $37.50K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | $12.50K 10-Q · filed 2021-05-14 | $25.00K derived: sum of 2 quarters · filed 2022-03-31 | $37.50K derived: sum of 3 quarters · filed 2022-03-31 | $50.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | $12.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $25.00K derived: sum of 2 quarters · filed 2022-03-31 | $37.50K derived: sum of 3 quarters · filed 2022-03-31 | $37.50K 10-K · filed 2022-03-31 |
| 2020-09-30 | $12.50K 10-Q · filed 2021-11-15 | $25.00K derived: sum of 2 quarters · filed 2021-11-15 | $25.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $12.50K 10-Q · filed 2021-08-16 | $12.50K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |